Fresenius Medical Care AG & Co. KGaA FMS
22.69
0.34
1.52%
as of 25 Sep
- Market cap
- $11.9B
- P/E
- 11.8×
Follow FMS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.72 | 11.87 | 12.47 | 19.22 |
+8 more quarters Free account |
P/S ratio |
0.54 | 0.55 | 0.62 | 0.71 | |
P/FCF ratio |
5.91 | 6.08 | 6.88 | 7.58 | |
P/Operating CF |
12.16 | 46.77 | 12.96 | 17.12 | |
P/B ratio |
0.77 | 0.75 | 0.86 | 0.95 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.85 | 0.86 | 0.89 | 0.98 | |
EV/EBITDA |
4.94 | 4.99 | 5.27 | 6.13 | |
EV/Operating CF |
5.95 | 6.18 | 6.54 | 7.51 | |
EV/FCF |
9.38 | 9.47 | 9.83 | 10.49 | |
Quick Ratio |
0.68 | 0.79 | 0.84 | 0.88 | |
Current Ratio |
1.07 | 1.20 | 1.26 | 1.36 | |
Net Debt/EBITDA |
7.41 | 7.89 | 5.62 | 5.90 | |
Debt/Assets |
24.18% | 23.95% | 23.56% | 22.23% | |
Debt/Equity |
0.56 | 0.53 | 0.51 | 0.49 | |
Asset Turnover |
0.63 | 0.63 | 0.62 | 0.60 | |
Operating CF/Net income |
3.93 | 1.93 | 2.89 | 2.80 | |
Capex/Depreciation |
(0.65) | (0.40) | (1.20) | (0.53) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.82% | 0.83% | 0.77% | 0.77% | |
Selling, General and Administrative Expense of Revenue |
15.14% | 16.24% | 15.50% | 14.44% | |
Intangible Assets out of Total Assets |
0.49 | 0.48 | 0.48 | 0.48 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.96) | (0.86) | (0.72) | (0.70) | |
Graham Number |
35.67 | 35.93 | 34.53 | 29.29 | |
Earnings Yield |
8.54% | 8.42% | 8.02% | 5.20% | |
Free Cash Flow Yield |
16.91% | 16.44% | 14.54% | 13.19% | |
Revenue per Share |
10.53 | 9.81 | 10.16 | 9.77 | |
Operating CF per Share |
1.86 | 0.48 | 1.84 | 1.54 | |
Capex per Share |
(0.51) | (0.40) | (0.78) | (0.40) | |
Free Cash Flow per Share |
1.35 | 0.08 | 1.06 | 1.14 | |
Cash per Share |
3.14 | 3.45 | 3.97 | 3.63 | |
Shareholders Equity per Share |
29.30 | 30.20 | 27.75 | 27.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.30 | 30.20 | 27.75 | 27.83 | |
Free Cash Flow |
726.32 | 46.70 | 615.48 | 664.35 | |
Working Capital |
595.00 | 1,613.32 | 1,870.54 | 2,413.76 | |
Capital Expenditures |
(272.21) | (218.85) | (454.85) | (234.06) | |
Net Current Asset Value |
(11,711.52) | (10,714.94) | (9,980.22) | (10,700.35) | |
EV/EBIT |
9.12 | 9.42 | 9.59 | 12.81 | |
Capex to Sales |
0.05 | 0.04 | 0.08 | 0.04 | |
Net Profit Margin |
4.49% | 2.55% | 6.27% | 5.63% | |
Price to Operating Income |
5.75 | 6.05 | 6.71 | 9.25 | |
| Other line items | |||||
Average Receivables |
3,848.67 | 4,066.39 | 3,640.01 | 3,716.73 | |
Average Payables |
945.16 | 992.97 | 1,005.24 | 960.72 | |
Average Inventory |
2,488.55 | 2,442.65 | 2,329.88 | 2,373.85 | |
Average Assets |
35,953.20 | 35,658.02 | 35,699.22 | 35,926.35 | |
Average Common Equity |
15,998.30 | 16,479.66 | 16,611.34 | 16,260.83 |
Columns are period end dates